AKAhmed Kayssi

Ahmed Kayssi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed Kayssi has a total of 210 co-authors. Here are the top co-authors by number of shared publications:

  • Daryl S Kucey

    Division of Vascular Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

    5 shared publications
  • Giuseppe Papia

    Division of Vascular Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

    5 shared publications
  • Thomas Forbes

    Division of Vascular Surgery, Toronto General Hospital, University of Toronto, Toronto, Canada

    5 shared publications
  • Andrew D Dueck

    Division of Vascular Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

    4 shared publications
  • Richard Neville

    INOVA Heart and Vascular Institute, Falls Church, Virginia, USA

    4 shared publications
  • Andrew Kucey

    Division of Vascular Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

    3 shared publications

Latest Publications

  • Open Access

    Twelve-month results of cyanoacrylate closure in patients with venous leg ulceration

    by Kathleen Gibson, Manjit Gohel, Ahmed Kayssi, Joseph Sabat, Nicolas Néaume, Leigh Ann O'BAnion, Paul Gagne, Misaki Kiguchi, Neil M. Khilnani, Raghu Kolluri, et al.

  • Assessing Challenges and Barriers to Effective Wound Care in Rural Indigenous Communities

    by Polycronis P. Akouris, Jonah W. Perlmutter, Arshia P. Javidan, Asha Behdinan, Jackie Walker, Ahmed Kayssi, R. Gary Sibbald, Rachel N. Asiniwasis

    OBJECTIVE: To explore the lived experiences of patients with chronic wounds from a remote Indigenous community in Northern Manitoba, Canada, focusing on challenges in wound management, the impact on quality of life, barriers to wound care access, and the role of traditional healing practices. METHODS: A qualitative descriptive study was co-created with members of the Nisichawayasihk Cree Nation (NCN) and conducted in alignment with OCAP (Ownership, Control, Access, and Possession) principles. Fifteen participants with current or past chronic wounds participated in semi-structured, in-person interviews at the NCN Family and Community Wellness Centre in June 2024. Interviews were audio-recorded, transcribed verbatim, and analyzed inductively using NVivo to identify key thematic domains. RESULTS: Five thematic domains emerged: (1) access to health care—limited local services, long wait times, and substantial travel and financial burden to obtain specialty care; (2) inadequate wound care—inconsistent follow-up and reliance on self-management at home; (3) patient education—focused largely on diabetes control with little wound-specific guidance; (4) living with pain—persistent pain limiting mobility, sleep, and emotional well-being; and (5) traditional Indigenous medicine—frequent use of culturally rooted treatments, though often not acknowledged or integrated by Western providers. CONCLUSIONS: Indigenous patients experience major barriers to timely, effective wound care, driven by geographic isolation, fragmented services, and gaps in patient education. Integrating traditional healing with Western practice, strengthening community-based care pathways, and improving specialist access may support limb preservation, reduce preventable amputation, and enhance quality of life.


  • Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs

    by Gar-Way Ma, Julien Bernatchez, Brianne Yarranton, Andrew D Dueck, Dheeraj K Rajan, Thomas L Forbes, Charles de Mestral, Ahmed Kayssi


  • Open Access

    Clinical evaluation of adults undergoing elective surgery utilizing intraoperative incisional wound irrigation (CLEAN Wound): protocol for a randomised controlled trial

    by Rachel Roke, Erin Lillie, Nick Daneman, Stephanie A Mason, George Tomlinson, Yidi Jiang, Jonah Shiroky, Sudarshani Puran, David E Smith, Jad Abou Khalil, et al.

    Introduction: In moderate to high-risk surgical procedures, 15–25% of patients develop a postoperative surgical site infection. Intraoperative incisional wound irrigation has the potential to reduce surgical site infections, and additional randomised controlled trials are required to provide evidence of effectiveness. Methods and analysis: This protocol describes a pragmatic, adaptive, participant and adjudicator-blinded trial at 13 sites in Canada in up to 2500 participants. Participants planned for surgery with an abdominal or groin incision, who are eligible and provide verbal consent through an integrated consent model, are randomised to receive intraoperative incisional wound irrigation with povidone-iodine, saline or no irrigation. The primary outcome is surgical site infection within 30 days postoperatively. Secondary outcomes include quality of life measured 30 days postoperatively and morbidity, mortality and healthcare utilisation within 90 days postoperatively. Ethics and dissemination: This trial has been approved by the research ethics board at the participating centres and stopped enrolling participants on May 23, 2025. All participants will provide verbal consent. Results will be disseminated via presentation at conferences, publication and posted on clinicaltrials.gov. Trial registration number: The study is registered with http://clinicaltrial.gov ( NCT04548661 ; 14 September 2020).

  • Ultrasound-guided versus anatomic landmark-guided percutaneous femoral artery access

    by Shira A Strauss, Gar-Way Ma, Chanhee Seo, Jeffrey J Siracuse, Sreekumar Madassery, Alexander G Truesdell, Keith Pereira, Ethan C Korngold, Ahmed Kayssi

    Background The use of percutaneous arterial access for endovascular procedures has broad applications, from diagnostic angiography in the coronary and peripheral arteries, to thromboembolectomy in people with ischemic stroke and percutaneous coronary intervention in those with acute myocardial infarction. The rise of these procedures worldwide underscores the importance of obtaining precise and timely arterial access while minimizing the risk of adverse events. Traditionally, anatomic landmarks, such as the anterior superior iliac spine and symphysis pubis, have guided percutaneous common femoral artery (CFA) access, along with manual palpation of the pulse and fluoroscopy to confirm bony landmarks. Anatomic landmarks can be deceptive, however, especially in certain subpopulations, such as those with a high femoral artery bifurcation, elevated body mass index (BMI), or non‐palpable femoral pulses. Ultrasound has emerged as a promising tool to guide percutaneous CFA access, offering enhanced visualization and providing real‐time guidance. Notwithstanding this theoretical advantage, trials have inconsistently demonstrated an advantage to ultrasound guidance over anatomic landmarks, and concerns surrounding added set‐up time and training have limited its uptake both clinically and across society guidelines. Objectives To assess the efficacy and safety of ultrasound compared to anatomic landmarks to guide percutaneous access of the CFA for the purpose of endovascular arterial imaging or treatment. Search methods The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 25 January 2024. Selection criteria We selected randomized controlled trials comparing ultrasound guidance to anatomic landmark guidance (using manual palpation or fluoroscopy, or both) for percutaneous CFA access in people undergoing endovascular therapy for diagnostic or therapeutic purposes. Data collection and analysis We used standard Cochrane methods. Primary outcomes included first‐pass success, time to successful CFA access, and major bleeding (including hematoma requiring transfusion, hematoma extending length of stay, hematoma ≥ 5 cm, unexplained hemoglobin drop, or major/severe bleeding as defined by each trial). Secondary outcomes included overall cannulation success, venipuncture, pain scores, number of access attempts, major complications (including retroperitoneal hematoma, pseudoaneurysms, dissections, arteriovenous fistulae, or occlusions), adverse events (including minor bleeding, infection, and neuropathy) up to 30 days, quality of life, re‐intervention rate up to 30 days, and total number of access sites attempted. We conducted sensitivity analyses to determine whether the effect of ultrasound guidance on time to successful CFA access differed across studies that defined this endpoint differently, and to assess the impact of studies that permitted rescue ultrasound on study endpoints. Main results Of 1422 records identified through our search of the databases, nine randomized controlled trials enrolling 4447 participants fulfilled our inclusion criteria. All trials were at high risk of bias in at least one domain, with seven trials at overall high risk of bias and the remaining two at overall unclear risk of bias. There may be increased first‐pass success (odds ratio [OR] 3.35, 95% confidence interval [CI] 2.53 to 4.44; P < 0.001, I² = 69%; 7 trials, 4274 participants; low certainty evidence) and reduced time to successful CFA access (mean difference [MD] −17.24 s, 95% CI −27.04 to −7.43 s; P < 0.001, I² = 45%; 6 trials, 3570 participants; low certainty evidence) with ultrasound guidance compared to anatomic landmark guidance. Ultrasound guidance may also reduce unintentional venipuncture (OR 0.26, 95% CI 0.18 to 0.38; P < 0.001, I² = 33%; 7 trials, 4178 participants; low certainty evidence) and number of access attempts (MD −0.59, 95% CI −0.91 to −0.26; P < 0.001, I² = 96%; 5 trials, 3362 participants; very low certainty evidence), although the evidence for the latter outcome is very uncertain. Ultrasound guidance may have little to no effect on major bleeding (OR 0.60, 95% CI 0.32 to 1.13; P = 0.11, I² = 38%; 6 trials, 4016 participants; low certainty evidence), overall cannulation success (though the evidence is very uncertain) (OR 1.46, 95% CI 0.93 to 2.30; P = 0.10, I² = 59%; 4 trials, 2520 participants; very low certainty evidence), and likely has little to no effect on pain scores (MD 0.00, 95% CI −0.34 to 0.34; P = 1.00, I² not applicable; 1 trial, 939 participants; moderate certainty evidence). Ultrasound guidance may also have little to no effect on retroperitoneal hematoma, pseudoaneurysm formation, arterial dissection, arteriovenous fistulae, target vessel occlusion, minor bleeding, or infection compared to anatomic landmark guidance (P > 0.05 for all). Lack of data precluded an assessment of re‐intervention rates, neuropathy, quality of life, or number of access sites. Sensitivity analysis revealed that ultrasound guidance may reduce time to successful CFA access in studies that defined this outcome as time from administration of local anesthetic to successful sheath insertion (MD −23.65 s, 95% CI −34.28 to −13.01 s; 3 trials, 1517 participants), but not in studies that defined it as time from the first movement of the fluoroscopy table/application of the ultrasound probe to successful sheath insertion (MD −14.85 s, 95% CI −33.45 to 3.75 s; 2 trials, 1941 participants) or time from skin penetration by the access needle to sheath insertion (MD 11.00 s, 95% CI −43.06 to 65.06 s; 1 trial, 112 participants)....


  • Fibromuscular Dysplasia, Carotid Kinks, and Other Rare Lesions

    by Dipankar Mukherjee, Bibhas Amatya, Ahmed Kayssi

  • Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia

    by Michael S. Conte, Alik Farber, Andrew Barleben, Emiliano Chisci, Gheorghe Doros, Vikram S. Kashyap, Ahmed Kayssi, Philippe Kolh, Carla C. Moreira, Timothy Nypaver, et al.

    BACKGROUND: The optimal strategy for lower extremity revascularization (surgical bypass versus endovascular intervention) in patients with chronic limb-threatening ischemia (CLTI) is unclear. We examined the effectiveness of open surgical bypass using single-segment great saphenous vein conduit (SSGSV), alternative conduits (AC), or endovascular interventions (ENDO) among patients with CLTI deemed acceptable for either open surgical bypass or ENDO treatment. METHODS: This was a planned as-treated analysis of the multicenter BEST-CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia) randomized controlled trial comparing open surgical bypass and ENDO for CLTI due to infrainguinal peripheral artery disease. Outcomes were tabulated based on the initial revascularization received: SSGSV bypass, AC bypass, and ENDO. Analyses were performed for all treated patients and then excluding those who experienced early technical failure. Multivariable Cox regression models were used. End points included the primary trial outcome (major adverse limb event [MALE] or all-cause death), major amputation, MALE at any time or perioperative (30-day) death, reintervention-amputation-death, and all-cause mortality. RESULTS: Among 1780 patients with CLTI, treatments received included SSGSV bypass (n=621), AC bypass (n=236), and ENDO (n=923) procedures. There were no significant differences in 30-day mortality, major adverse cardiovascular events, or serious adverse events; subjects treated with ENDO experienced greater MALE within 30 days (13.1% versus 2.7%, 3% for SSGSV, AC; P P P =0.017), MALE or perioperative death (hazard ratio, 0.51 [0.41–0.62]; P P <0.001). AC bypass was associated with reduced MALE or perioperative death and reintervention-amputation-death compared with ENDO. Significant benefits of SSGSV over ENDO remained when excluding patients who experienced early technical failure. There were no significant differences in long-term mortality by initial treatment received. When analyzed by the level of disease treated, the improved outcomes of SSGSV were greatest among patients who underwent femoropopliteal revascularization. CONCLUSIONS: Analysis of as-treated outcomes from the BEST-CLI trial demonstrates the safety and clinical superiority of bypass with SSGSV among patients with CLTI who were deemed suitable for either open surgical bypass or ENDO revascularization. Assessment of great saphenous vein quality should be incorporated into the evaluation of patients with CLTI who are surgical candidates. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02060630 and NCT02060630.


  • In the know with toe and flow

    by Ahmed Kayssi, Samantha Minc, David G. Armstrong


  • The role of sealants for achieving anastomotic hemostasis in vascular surgery

    by Gar-Way Ma, Andrew Kucey, Sam C Tyagi, Giuseppe Papia, Daryl S Kucey, Ramon L Varcoe, Thomas Forbes, Richard Neville, Andrew D Dueck, Ahmed Kayssi

    Background During vascular interventions, connections that link arteries, veins, or synthetic grafts, which are known as an ‘anastomosis', may be necessary. Vascular anastomoses can bleed from the needle holes that result from the creation of the anastomoses. Various surgical options are available for achieving hemostasis, or the stopping of bleeding, including the application of sealants directly onto the bleeding vessels or tissues. Sealants are designed for use in vascular surgery as adjuncts when conventional interventions are ineffective and are applied directly by the surgeon to seal bleeding anastomoses. Despite the availability of several different types of sealants, the evidence for the clinical efficacy of these hemostatic adjuncts has not been definitively established in vascular surgery patients. Objectives To evaluate the benefits and harms of sealants as adjuncts for achieving anastomotic site hemostasis in patients undergoing vascular surgery. Search methods The Cochrane Vascular Information Specialist conducted systematic searches of the following databases: the Cochrane Vascular Specialised Register via the Cochrane Register of Studies; the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE via Ovid; Embase via Ovid ; and CINAHL via EBSCO. We also searched ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform for clinical trials. Reference lists of included trials and relevant reviews were also searched. The latest search date was 6 March 2023. Selection criteria We included randomized controlled trials that compared fibrin or synthetic sealant use with alternative interventions (e.g. manual compression, reversal of anticoagulation) for achieving anastomotic‐site hemostasis in vascular surgery procedures. We included participants who underwent the creation of an anastomosis during vascular surgery. We excluded non‐vascular surgery patients. Data collection and analysis We have used standard Cochrane methods. Our primary outcomes were time to hemostasis, failure of hemostatic intervention, and intraoperative blood loss. Our secondary outcomes were operating time, death from bleeding complications up to 30 days, postoperative bleeding up to 30 days, unplanned return to the operating room for bleeding complications management up to 30 days, quality of life, and adverse events. We used GRADE to assess the certainty of evidence for each outcome. Main results We found 24 randomized controlled trials that included a total of 2376 participants who met the inclusion criteria. All trials compared sealant use with standard care controls, including oxidized cellulose, gelatin sponge, and manual compression. All trials were at high risk of performance bias, detection bias, and other sources of bias. We downgraded the certainty of evidence for risk of bias concerns, inconsistency, imprecision and possible publication bias. Combining data on time to hemostasis showed that sealant use may reduce the mean time to hemostasis compared to control (mean difference (MD) ‐230.09 seconds, 95% confidence interval (CI) ‐329.24 to ‐130.94; P < 0.00001; 7 studies, 498 participants; low‐certainty evidence). Combining data on failure of hemostatic intervention showed that sealant use may reduce the rate of failure compared to control, but the evidence is very uncertain (risk ratio (RR) 0.46, 95% CI 0.35 to 0.61; P < 0.00001; 17 studies, 2120 participants; very low‐certainty evidence). We did not detect any clear differences between the sealant and control groups for intraoperative blood loss (MD ‐32.69 mL, 95% CI ‐96.21 to 30.83; P = 0.31; 3 studies, 266 participants; low‐certainty evidence); operating time (MD ‐18.72 minutes, 95% CI ‐40.18 to 2.73; P = 0.09; 4 studies, 436 participants; low‐certainty evidence); postoperative bleeding (RR 0.78, 95% CI 0.59 to 1.04; P = 0.09; 9 studies, 1216 participants; low‐certainty evidence), or unplanned return to the operating room (RR 0.27, 95% CI 0.04 to 1.69; P = 0.16; 8 studies, 721 participants; low‐certainty evidence). No studies reported death from bleeding or quality of life outcomes. Authors' conclusions Based on meta‐analysis of 24 trials with 2376 participants, our review demonstrated that sealant use for achieving anastomotic hemostasis in vascular surgery patients may result in reduced time to hemostasis, and may reduce rates of hemostatic intervention failure, although the evidence is very uncertain, when compared to standard controls. Our analysis showed there may be no differences in intraoperative blood loss, operating time, postoperative bleeding up to 30 days, and unplanned return to the operating room for bleeding complications up to 30 days. Deaths and quality of life could not be analyzed. Limitations include the risk of bias in all studies. Our review has demonstrated that using sealants may reduce the time required to achieve hemostasis and the rate of hemostatic failure. However, a significant risk of bias was identified in the included studies, and future trials are needed to provide unbiased data and address other considerations such as cost‐effectiveness and adverse events with sealant use.


  • Quality of Life in Patients With Chronic Limb-Threatening Ischemia Treated With Revascularization

    by Matthew T Menard, Alik Farber, Richard J Powell, Kenneth Rosenfield, Michael S Conte, Taye H Hamza, John A Kaufman, Mark J Cziraky, Mark A Creager, Michael D Dake, et al.

    BACKGROUND: In the BEST-CLI trial (Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb-Threatening Ischemia), a prespecified secondary objective was to assess the effects of revascularization strategy on health-related quality of life (HRQoL). METHODS: Patients with chronic limb-threatening ischemia were randomized to surgical bypass (Bypass) or endovascular intervention (Endo) in 2 parallel trials. Cohort 1 included patients with single-segment great saphenous vein; cohort 2 included those lacking suitable single-segment great saphenous vein. HRQoL was assessed over the trial duration using Vascular Quality-of-Life (VascuQoL), European Quality-of-Life-5D (EQ-5D), the Short Form-12 (SF-12) Physical Component Summary (SF-12 PCS), SF-12 Mental Component Summary (SF-12 MCS), Utility Index Score (SF-6D R2), and numeric rating scales of pain. HRQoL was summarized by cohort and compared within and between groups using mixed-model linear regression. RESULTS: A total of 1193 and 335 patients in cohorts 1 and 2 with a mean follow-up of 2.9 and 2.0 years, respectively, were analyzed. In cohort 1, HRQoL significantly improved from baseline to follow-up for both groups across all measures. For example, mean (SD) VascuQoL scores were 3.0 (1.3) and 3.0 (1.2) for Bypass and Endo at baseline and 4.7 (1.4) and 4.8 (1.5) over follow-up. There were significant group differences favoring Endo when assessed with VascuQoL (difference, –0.14 [95% CI, –0.25 to –0.02]; P =0.02), SF-12 MCS (difference, –1.03 [95% CI, –1.89 to –0.18]; P =0.02), SF-6D R2 (difference, –0.01 [95% CI, –0.02 to –0.001]; P =0.03), numeric rating scale pain at present (difference, 0.26 [95% CI, 0.03 to 0.49]; P =0.03), usual level during previous week (difference, 0.26 [95% CI, 0.04 to 0.48]; P =0.02), and worst level during previous week (difference, 0.29 [95% CI, 0.02 to 0.56]; P =0.04). There was no difference between treatment arms on the basis of EQ-5D (difference, –0.01 [95% CI, –0.03 to 0.004]; P =0.12) or SF-12 PCS (difference, –0.41 [95% CI, –1.2 to 0.37]; P =0.31). In cohort 2, HRQoL also significantly improved from baseline to the end of follow-up for both groups based on all measures, but there were no differences between Bypass and Endo on any measure. CONCLUSIONS: Among patients with chronic limb-threatening ischemia deemed eligible for either Bypass or Endo, revascularization resulted in significant and clinically meaningful improvements in HRQoL. In patients with an available single-segment great saphenous vein for bypass, but not among those without one, Endo was statistically superior on some HRQoL measures; however, these differences were below the threshold of clinically meaningful difference.